Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis

Metformin was proposed to be a candidate for host-directed therapy for COVID-19. However, its efficacy remains to be validated. In this study, we compared the outcome of metformin users and nonusers in hospitalized COVID-19 patients with diabetes. Hospitalized diabetic patients with confirmed COVID-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of tropical medicine and hygiene Jg. 103; H. 1; S. 69
Hauptverfasser:	Luo, Pan, Qiu, Lin, Liu, Yi, Liu, Xiu-Lan, Zheng, Jian-Ling, Xue, Hui-Ying, Liu, Wen-Hua, Liu, Dong, Li, Juan
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.07.2020
Schlagworte:	Aged Betacoronavirus China Coronavirus Infections - complications Coronavirus Infections - mortality Coronavirus Infections - therapy COVID-19 Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Female Hospital Mortality Humans Hypoglycemic Agents - therapeutic use Length of Stay Male Metformin - therapeutic use Middle Aged Pandemics Pneumonia, Viral - complications Pneumonia, Viral - mortality Pneumonia, Viral - therapy Retrospective Studies SARS-CoV-2 China
ISSN:	1476-1645, 1476-1645
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Metformin was proposed to be a candidate for host-directed therapy for COVID-19. However, its efficacy remains to be validated. In this study, we compared the outcome of metformin users and nonusers in hospitalized COVID-19 patients with diabetes. Hospitalized diabetic patients with confirmed COVID-19 in the Tongji Hospital of Wuhan, China, from January 27, 2020 to March 24, 2020, were grouped into metformin and no-metformin groups according to the diabetic medications used. The demographics, characteristics, laboratory parameters, treatments, and clinical outcome in these patients were retrospectively assessed. A total of 283 patients (104 in the metformin and 179 in the no-metformin group) were included in this study. There were no significant differences between the two groups in gender, age, underlying diseases, clinical severity, and oxygen-support category at admission. The fasting blood glucose level of the metformin group was higher than that of the no-metformin group at admission and was under effective control in both groups after admission. Other laboratory parameters at admission and treatments after admission were not different between the two groups. The length of hospital stay did not differ between the two groups (21.0 days for metformin versus 19.5 days for no metformin, = 0.74). However, in-hospital mortality was significantly lower in the metformin group (3/104 (2.9%) versus 22/179 (12.3%), = 0.01). Antidiabetic treatment with metformin was associated with decreased mortality compared with diabetics not receiving metformin. This retrospective analysis suggests that metformin may offer benefits in patients with COVID-19 and that further study is indicated.
AbstractList	Metformin was proposed to be a candidate for host-directed therapy for COVID-19. However, its efficacy remains to be validated. In this study, we compared the outcome of metformin users and nonusers in hospitalized COVID-19 patients with diabetes. Hospitalized diabetic patients with confirmed COVID-19 in the Tongji Hospital of Wuhan, China, from January 27, 2020 to March 24, 2020, were grouped into metformin and no-metformin groups according to the diabetic medications used. The demographics, characteristics, laboratory parameters, treatments, and clinical outcome in these patients were retrospectively assessed. A total of 283 patients (104 in the metformin and 179 in the no-metformin group) were included in this study. There were no significant differences between the two groups in gender, age, underlying diseases, clinical severity, and oxygen-support category at admission. The fasting blood glucose level of the metformin group was higher than that of the no-metformin group at admission and was under effective control in both groups after admission. Other laboratory parameters at admission and treatments after admission were not different between the two groups. The length of hospital stay did not differ between the two groups (21.0 days for metformin versus 19.5 days for no metformin, = 0.74). However, in-hospital mortality was significantly lower in the metformin group (3/104 (2.9%) versus 22/179 (12.3%), = 0.01). Antidiabetic treatment with metformin was associated with decreased mortality compared with diabetics not receiving metformin. This retrospective analysis suggests that metformin may offer benefits in patients with COVID-19 and that further study is indicated. Metformin was proposed to be a candidate for host-directed therapy for COVID-19. However, its efficacy remains to be validated. In this study, we compared the outcome of metformin users and nonusers in hospitalized COVID-19 patients with diabetes. Hospitalized diabetic patients with confirmed COVID-19 in the Tongji Hospital of Wuhan, China, from January 27, 2020 to March 24, 2020, were grouped into metformin and no-metformin groups according to the diabetic medications used. The demographics, characteristics, laboratory parameters, treatments, and clinical outcome in these patients were retrospectively assessed. A total of 283 patients (104 in the metformin and 179 in the no-metformin group) were included in this study. There were no significant differences between the two groups in gender, age, underlying diseases, clinical severity, and oxygen-support category at admission. The fasting blood glucose level of the metformin group was higher than that of the no-metformin group at admission and was under effective control in both groups after admission. Other laboratory parameters at admission and treatments after admission were not different between the two groups. The length of hospital stay did not differ between the two groups (21.0 days for metformin versus 19.5 days for no metformin, P = 0.74). However, in-hospital mortality was significantly lower in the metformin group (3/104 (2.9%) versus 22/179 (12.3%), P = 0.01). Antidiabetic treatment with metformin was associated with decreased mortality compared with diabetics not receiving metformin. This retrospective analysis suggests that metformin may offer benefits in patients with COVID-19 and that further study is indicated.Metformin was proposed to be a candidate for host-directed therapy for COVID-19. However, its efficacy remains to be validated. In this study, we compared the outcome of metformin users and nonusers in hospitalized COVID-19 patients with diabetes. Hospitalized diabetic patients with confirmed COVID-19 in the Tongji Hospital of Wuhan, China, from January 27, 2020 to March 24, 2020, were grouped into metformin and no-metformin groups according to the diabetic medications used. The demographics, characteristics, laboratory parameters, treatments, and clinical outcome in these patients were retrospectively assessed. A total of 283 patients (104 in the metformin and 179 in the no-metformin group) were included in this study. There were no significant differences between the two groups in gender, age, underlying diseases, clinical severity, and oxygen-support category at admission. The fasting blood glucose level of the metformin group was higher than that of the no-metformin group at admission and was under effective control in both groups after admission. Other laboratory parameters at admission and treatments after admission were not different between the two groups. The length of hospital stay did not differ between the two groups (21.0 days for metformin versus 19.5 days for no metformin, P = 0.74). However, in-hospital mortality was significantly lower in the metformin group (3/104 (2.9%) versus 22/179 (12.3%), P = 0.01). Antidiabetic treatment with metformin was associated with decreased mortality compared with diabetics not receiving metformin. This retrospective analysis suggests that metformin may offer benefits in patients with COVID-19 and that further study is indicated.
Author	Qiu, Lin Zheng, Jian-Ling Liu, Wen-Hua Liu, Yi Xue, Hui-Ying Li, Juan Luo, Pan Liu, Dong Liu, Xiu-Lan
Author_xml	– sequence: 1 givenname: Pan surname: Luo fullname: Luo, Pan organization: 1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China – sequence: 2 givenname: Lin surname: Qiu fullname: Qiu, Lin organization: 1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China – sequence: 3 givenname: Yi surname: Liu fullname: Liu, Yi organization: 1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China – sequence: 4 givenname: Xiu-Lan surname: Liu fullname: Liu, Xiu-Lan organization: 1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China – sequence: 5 givenname: Jian-Ling surname: Zheng fullname: Zheng, Jian-Ling organization: 1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China – sequence: 6 givenname: Hui-Ying surname: Xue fullname: Xue, Hui-Ying organization: 1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China – sequence: 7 givenname: Wen-Hua surname: Liu fullname: Liu, Wen-Hua organization: 2Clinical Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China – sequence: 8 givenname: Dong surname: Liu fullname: Liu, Dong organization: 1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China – sequence: 9 givenname: Juan surname: Li fullname: Li, Juan organization: 1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/32446312$$D View this record in MEDLINE/PubMed
BookMark	eNpNkEtLAzEURoNU7EOXbiVLN1PzmmRmWVofBUtFqi5LJrmhKfOok1Spv94RK7i63-U75y7uEPXqpgaELikZCybzG72N1WbMSEK4Sk_QgAolEypF2vuX-2gYwpYQmjFKz1CfMyEkp2yAvhYQXdNWvsarFnSsoI74TQc8CaExXkew-NPHDZ6B6frQrYumjbr08YA7abp8nc8SmuMnHX3nhiPtdQERwg-i8TPEtgk7MNF_AJ7UujwEH87RqdNlgIvjHKGXu9vV9CF5XN7Pp5PHxAjBY6KNKDJqrVDOuJRYAiLLheJcU5E6limVAaeqyEHqVBvOcmOs48Jl0kFhLRuh69-7u7Z530OI68oHA2Wpa2j2Yc0EkalUGVcdenVE90UFdr1rfaXbw_rvX-wbtadwFw
CitedBy_id	crossref_primary_10_3389_fimmu_2021_733921 crossref_primary_10_3389_fphar_2020_592439 crossref_primary_10_1016_j_obmed_2020_100290 crossref_primary_10_1016_j_ejphar_2021_173934 crossref_primary_10_20473_fmi_v59i3_46944 crossref_primary_10_3389_fendo_2022_1002834 crossref_primary_10_3389_fendo_2023_1128622 crossref_primary_10_1016_j_arr_2020_101167 crossref_primary_10_3390_medicina59101810 crossref_primary_10_3389_fphys_2021_749770 crossref_primary_10_3390_pharmaceutics13081170 crossref_primary_10_1016_j_diabres_2021_108936 crossref_primary_10_1073_pnas_2012363117 crossref_primary_10_1172_JCI170236 crossref_primary_10_3389_fendo_2024_1482853 crossref_primary_10_1007_s00005_022_00650_z crossref_primary_10_1016_j_dsx_2020_08_003 crossref_primary_10_1007_s11357_020_00261_6 crossref_primary_10_1136_bmjopen_2021_050051 crossref_primary_10_20900_immunometab20210001 crossref_primary_10_1016_j_lfs_2024_123202 crossref_primary_10_1016_j_cmet_2020_08_013 crossref_primary_10_1016_j_pcd_2022_10_001 crossref_primary_10_3390_v14071493 crossref_primary_10_1002_iid3_949 crossref_primary_10_1038_s41392_022_01043_6 crossref_primary_10_3389_fnut_2020_581680 crossref_primary_10_1002_jmv_26728 crossref_primary_10_1155_2021_1901772 crossref_primary_10_1111_imr_12977 crossref_primary_10_1016_j_biopha_2021_112230 crossref_primary_10_7861_clinmed_2020_0348 crossref_primary_10_1002_jmv_28635 crossref_primary_10_14341_omet12663 crossref_primary_10_1186_s40001_023_01389_9 crossref_primary_10_3390_biology11030400 crossref_primary_10_1016_j_diabres_2021_108925 crossref_primary_10_1186_s13098_021_00695_8 crossref_primary_10_3389_fendo_2021_708494 crossref_primary_10_1038_s41598_022_09639_2 crossref_primary_10_1016_j_lfs_2021_119371 crossref_primary_10_1016_j_metabol_2022_155196 crossref_primary_10_1007_s13300_021_01170_3 crossref_primary_10_1016_S2213_8587_21_00050_4 crossref_primary_10_3389_fcimb_2020_608435 crossref_primary_10_3390_biom11121834 crossref_primary_10_2217_fmb_2021_0116 crossref_primary_10_1016_j_compbiomed_2022_105601 crossref_primary_10_1016_j_diabet_2020_10_006 crossref_primary_10_1155_2022_8030765 crossref_primary_10_1371_journal_pone_0282210 crossref_primary_10_3389_fendo_2021_731974 crossref_primary_10_1016_j_jdiacomp_2020_107671 crossref_primary_10_1515_jbcpp_2020_0495 crossref_primary_10_1186_s12902_020_00626_0 crossref_primary_10_1093_jn_nxab059 crossref_primary_10_1111_jdi_13484 crossref_primary_10_2174_0929867331666230717154101 crossref_primary_10_1038_d41586_020_02856_7 crossref_primary_10_3390_v16121938 crossref_primary_10_4093_dmj_2020_0146 crossref_primary_10_1016_j_numecd_2021_02_020 crossref_primary_10_1016_j_virusres_2022_199010 crossref_primary_10_3390_nu14020321 crossref_primary_10_1093_ofid_ofab336 crossref_primary_10_1111_febs_16105 crossref_primary_10_3389_fgene_2021_765247 crossref_primary_10_1016_j_biopha_2021_111685 crossref_primary_10_3390_ijms232012470 crossref_primary_10_1002_jmv_26873 crossref_primary_10_1016_j_dsx_2020_11_006 crossref_primary_10_3390_ijms25105190 crossref_primary_10_1016_j_exger_2020_111197 crossref_primary_10_3389_fendo_2020_581839 crossref_primary_10_1080_09205063_2021_1975020 crossref_primary_10_3389_fmed_2021_704666 crossref_primary_10_3389_fcvm_2020_593061 crossref_primary_10_5501_wjv_v10_i3_86 crossref_primary_10_1007_s00125_021_05458_8 crossref_primary_10_1007_s10787_022_00988_y crossref_primary_10_1016_j_drudis_2021_11_002 crossref_primary_10_3389_fcimb_2023_1098712 crossref_primary_10_1002_edm2_338 crossref_primary_10_1007_s00284_021_02396_x crossref_primary_10_37586_2686_8636_4_2021_414_419 crossref_primary_10_1016_j_dsx_2020_09_009 crossref_primary_10_1186_s43556_022_00108_w crossref_primary_10_3390_jcm11185454 crossref_primary_10_3390_ijms241612782 crossref_primary_10_31482_mmsl_2022_004 crossref_primary_10_1016_j_diabres_2020_108619 crossref_primary_10_1080_07853890_2024_2425829 crossref_primary_10_2337_dc21_2186 crossref_primary_10_1016_j_molstruc_2024_138830 crossref_primary_10_1007_s12519_022_00662_x crossref_primary_10_1016_j_diabres_2021_108977 crossref_primary_10_1007_s11606_022_07701_3 crossref_primary_10_1111_aji_13518 crossref_primary_10_1080_14656566_2020_1837114 crossref_primary_10_1016_j_cmet_2020_11_014 crossref_primary_10_1002_rmv_2211 crossref_primary_10_1038_s41419_021_03513_1 crossref_primary_10_1111_bcp_15100 crossref_primary_10_1007_s00592_022_01861_8 crossref_primary_10_1016_j_immuni_2021_05_004 crossref_primary_10_1038_s43856_021_00033_z crossref_primary_10_2147_DHPS_S272411 crossref_primary_10_1007_s11940_020_00648_y crossref_primary_10_1007_s11010_021_04200_7 crossref_primary_10_1016_j_tim_2021_03_004 crossref_primary_10_1097_TP_0000000000004251 crossref_primary_10_3389_fimmu_2020_02056 crossref_primary_10_4158_EP_2020_0466 crossref_primary_10_1007_s10157_025_02755_z crossref_primary_10_3389_fphys_2021_730048 crossref_primary_10_3389_fphar_2021_622262 crossref_primary_10_1016_j_jdiacomp_2022_108391 crossref_primary_10_52586_S563 crossref_primary_10_1016_j_jamda_2020_10_031 crossref_primary_10_3390_microorganisms11030612 crossref_primary_10_3389_fimmu_2021_796855 crossref_primary_10_1016_j_mehy_2020_110374 crossref_primary_10_3390_jcm10163507 crossref_primary_10_3390_v13010090 crossref_primary_10_1002_jmv_26498 crossref_primary_10_1210_clinem_dgab067 crossref_primary_10_3389_fphar_2022_784459 crossref_primary_10_3389_fendo_2021_645194 crossref_primary_10_3389_fendo_2022_895458 crossref_primary_10_4239_wjd_v11_i11_481 crossref_primary_10_1007_s40292_021_00475_5 crossref_primary_10_1016_j_compbiomed_2020_104123 crossref_primary_10_1016_j_intimp_2021_108516 crossref_primary_10_1016_j_genrep_2022_101619 crossref_primary_10_1007_s43441_024_00633_6 crossref_primary_10_1016_j_dsx_2021_02_022 crossref_primary_10_1016_j_tjnut_2024_07_001 crossref_primary_10_3390_ijms22147605 crossref_primary_10_3389_fendo_2022_810914 crossref_primary_10_1056_NEJMoa2201662 crossref_primary_10_4103_jdmimsu_jdmimsu_155_23 crossref_primary_10_14341_omet12801 crossref_primary_10_1016_j_crmeth_2023_100503 crossref_primary_10_1016_j_dsx_2022_102602 crossref_primary_10_1007_s00592_020_01666_7 crossref_primary_10_1080_10715762_2020_1866757 crossref_primary_10_1038_s41574_020_00435_4 crossref_primary_10_1177_10815589251327511 crossref_primary_10_3390_nu13010047 crossref_primary_10_3389_fendo_2021_587801 crossref_primary_10_3390_biomedicines10123113 crossref_primary_10_1002_jcb_30683 crossref_primary_10_1007_s11239_022_02631_7 crossref_primary_10_1016_j_diabet_2020_101216 crossref_primary_10_1080_14656566_2023_2215385 crossref_primary_10_1177_1060028021999473 crossref_primary_10_3389_fendo_2021_772865 crossref_primary_10_1038_s41392_022_00952_w crossref_primary_10_4239_wjd_v13_i12_1154 crossref_primary_10_1007_s11845_021_02823_9 crossref_primary_10_1146_annurev_med_042220_011857 crossref_primary_10_1016_j_lfs_2021_119201 crossref_primary_10_7759_cureus_77288 crossref_primary_10_3389_fimmu_2022_1025495 crossref_primary_10_1007_s40256_021_00490_w crossref_primary_10_1016_j_arcmed_2021_08_002 crossref_primary_10_1186_s43556_022_00077_0 crossref_primary_10_4103_ajprhc_ajprhc_143_24 crossref_primary_10_1186_s12979_020_00204_x crossref_primary_10_1002_mco2_115 crossref_primary_10_3390_biomedicines11051246 crossref_primary_10_3390_jcm10051022 crossref_primary_10_3389_fendo_2020_600439 crossref_primary_10_1016_j_diabet_2020_07_006 crossref_primary_10_1038_s41392_023_01510_8 crossref_primary_10_1016_j_diabres_2022_109813 crossref_primary_10_1016_j_eprac_2023_06_001
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.4269/ajtmh.20-0375
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1476-1645
ExternalDocumentID	32446312
Genre	Journal Article
GeographicLocations	China
GeographicLocations_xml	– name: China
GroupedDBID	--- .55 .GJ 1CY 23M 2WC 34G 36B 3O- 53G 5GY 5RE 5VS 6J9 ABCQX ABPPZ ABTNK ACGFO ADBBV ADTPD AENEX AFFNX AGCDD AI. AIAGR ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CGR CUY CVF DIK E3Z EBD EBS ECM EIF EJD EMB EMOBN F5P GX1 H13 HYE K-O KQ8 L7B MV1 NEJ NPM OHT OK1 P2P PKN PQQKQ RHF RHI RPM SV3 TR2 TST UPT VH1 W8F WH7 WOQ WOW X7M XOL ZGI ZKB ZXP ~KM 7X8
ID	FETCH-LOGICAL-c443t-ac4b81dd47fcf50d0e4894733a145f28778e317b9e6a5ac329ccdf34f86febdd2
IEDL.DBID	7X8
ISICitedReferencesCount	215
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000577191000021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1476-1645
IngestDate	Thu Jul 10 17:22:42 EDT 2025 Wed Feb 19 02:25:53 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c443t-ac4b81dd47fcf50d0e4894733a145f28778e317b9e6a5ac329ccdf34f86febdd2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://www.ajtmh.org/downloadpdf/view/journals/tpmd/103/1/article-p69.pdf
PMID	32446312
PQID	2406567837
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2406567837 pubmed_primary_32446312
PublicationCentury	2000
PublicationDate	2020-07-01
PublicationDateYYYYMMDD	2020-07-01
PublicationDate_xml	– month: 07 year: 2020 text: 2020-07-01 day: 01
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	The American journal of tropical medicine and hygiene
PublicationTitleAlternate	Am J Trop Med Hyg
PublicationYear	2020
References	32711585 - Am J Trop Med Hyg. 2020 Sep;103(3):1337-1338
References_xml	– reference: 32711585 - Am J Trop Med Hyg. 2020 Sep;103(3):1337-1338
SSID	ssj0018211
Score	2.664288
Snippet	Metformin was proposed to be a candidate for host-directed therapy for COVID-19. However, its efficacy remains to be validated. In this study, we compared the...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	69
SubjectTerms	Aged Betacoronavirus China Coronavirus Infections - complications Coronavirus Infections - mortality Coronavirus Infections - therapy COVID-19 Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Female Hospital Mortality Humans Hypoglycemic Agents - therapeutic use Length of Stay Male Metformin - therapeutic use Middle Aged Pandemics Pneumonia, Viral - complications Pneumonia, Viral - mortality Pneumonia, Viral - therapy Retrospective Studies SARS-CoV-2
Title	Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis
URI	https://www.ncbi.nlm.nih.gov/pubmed/32446312 https://www.proquest.com/docview/2406567837
Volume	103
WOSCitedRecordID	wos000577191000021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qinjx_VhfRPAadtukTXsSWV300HWRVfdW0jxgBdt1Wz346520KXsSBC-FQgIhM5l8M99kBqErz2gGC6TE92TfFtU2JM5sihUVljeiKmNNswk-GkXTaTx2AbfSpVW2NrE21KqQNkbeszdPAJaV8uv5B7Fdoyy76lporKIOBShjU7r4dMkiRH7df9djPCTgFgRNjU37eLMn3qp3y0UQ2wP2d3RZ3zLD7f-ubwdtOXyJbxqF2EUrOt9DG4lj0PfRd6Iri1NnOZ60Oeb4VZS4lZNW2MZm8W2NJ0v4TWqEDmgdw6TB48vDLfFiPG4KspZutAvh2iECP-lqUbRvOHFb9-QAPQ_vJoN74vovEMkYrYiQLAM4qxg30gR91dcsihkHMXosMOBq8UgD_MhiHYpASOrHUipDmYlCozOl_EO0lhe5PkZY0VBlAmTEtWBSBQJQAXh-gkqfMkX7XXTZ7moK-m1JC5Hr4rNMl_vaRUeNaNJ5U4gjBTDIQur5J3-YfYo2fesq15m2Z6hj4HTrc7Quv6pZubioFQe-o3HyA_rvzuQ
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Metformin+Treatment+Was+Associated+with+Decreased+Mortality+in+COVID-19+Patients+with+Diabetes+in+a+Retrospective+Analysis&rft.jtitle=The+American+journal+of+tropical+medicine+and+hygiene&rft.au=Luo%2C+Pan&rft.au=Qiu%2C+Lin&rft.au=Liu%2C+Yi&rft.au=Liu%2C+Xiu-Lan&rft.date=2020-07-01&rft.eissn=1476-1645&rft.volume=103&rft.issue=1&rft.spage=69&rft_id=info:doi/10.4269%2Fajtmh.20-0375&rft_id=info%3Apmid%2F32446312&rft_id=info%3Apmid%2F32446312&rft.externalDocID=32446312
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-1645&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-1645&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-1645&client=summon